Aortic preadipocyte differentiation into adipocytes induced by rosiglitazone in an in vitro model

被引:0
作者
Miguel R. Reyes
Brissia Lazalde
机构
[1] Universidad Juarez del Estado de Durango,Department of Pharmacology, Faculty of Medicine
[2] Universidad Juarez del Estado de Durango,Department of Genetics, Faculty of Medicine
[3] Mexican Institute of Social Security,Biomedical Research Unit
来源
In Vitro Cellular & Developmental Biology - Animal | 2007年 / 43卷
关键词
Adipocytes; Differentiation; PPARγ; Rosiglitazone; Thiazolidinediones; Tissue culture;
D O I
暂无
中图分类号
学科分类号
摘要
Peroxisome proliferator-activated receptor γ (PPARγ) is a key transcription factor for adipocyte differentiation. Preadipocyte differentiation into adipocytes from precursors in blood vessels is an important issue related to atherosclerotic cardiovascular disease; however, it has been poorly studied because of lack of experimental models. Our aim was to evaluate the potential of primary outgrowths derived from rat aortic rings as a model for studying the preadipocyte differentiation from aortic precursors induced by thiazolidinediones, which are exogenous ligands for PPARγ. Cell outgrowths derived from rat aortic rings were cultured and incubated with rosiglitazone at 1–1,000 nM; presence of lipid droplets was evaluated by oil red O staining. Rosiglitazone at 100 nM exerted a clear adipogenic effect inferred from the cells filled with fine and medium size lipidic droplets; this effect was extreme at 1,000 nM with cells showing lipidic macrodroplets. These results showed that cultures derived from aortic rings are a useful model for studying arterial preadipocyte differentiation.
引用
收藏
页码:159 / 161
页数:2
相关论文
共 48 条
  • [1] Blaschke F.(2006)Vascular effects of TZDs: new implications Vascul. Pharmacol. 45 3-18
  • [2] Spanheimer R.(2005)Microvascular endothelial cells sustain preadipocyte viability under hypoxic conditions In Vitro Cell Dev. Biol. Anim. 41 160-164
  • [3] Khan M.(2005)A nuclear receptor atlas: 3T3-L1 adipogenesis Mol. Endocrinol. 19 2437-2450
  • [4] Law R. E.(2004)Determination of rosiglitazone in coated tablets by MEKC and HPLC methods J. Pharm. Biomed. Anal. 36 909-913
  • [5] Frye C.(2004)Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease Hypertension 43 297-305
  • [6] Wu X.(2003)PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int. J. Obes. Relat. Metab. Disord. 27 147-161
  • [7] Patrick C.(2007)Temporal and spatial variations of lipid droplets during adipocyte division and differentiation J. Lipid Res. 48 9-18
  • [8] Fu M.(2003)Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone Hepatology 38 1008-1017
  • [9] Sun T.(2004)Adipogenesis: usefulness of in vitro and in vivo experimental models Anim. Sci. 82 905-915
  • [10] Bookout A. L.(2005)Essential role of fibroblast growth factor signaling in preadipocyte differentiation J. Clin. Endocrinol. Metab. 90 1226-1232